

We missed our luncheon appointment early in February. What are the chances of getting together during the next month?

Sincerely yours,
March 13, 1969

Dr. William R. Tabor
Director, Medical Research
A. H. Robins Company
1407 Cummings Drive
Richmond, Virginia 23220

MF:kp

Dear Bill,
Approval for the AHR-1900 study has just been received. The forms that you suggested should be sent as soon as possible.
(1) Tybamate paper on Drug Dependence: We have received the galley proof on the tybamate report from the *Journal of Clinical Pharmacology* and have ordered 300 reprints for our use. If Mrs. Carneal would like to order an additional supply, please have her call my secretary.

(2) Butaperazine Syrum Study: This study has appeared in *Current Therapeutic Research*; however, we have not yet received reprints.

(3) AHR-1900: With regard to Mr. Banner and the City of New York with regard to AHR-1900, I called him and he was principally interested in a general statement about AHR-1900. After our discussion he indicated that he would approve this study. He was surprised by the request from the Commissioner of Hospitals, indicating that this was the first such request that he had received in twenty years. We have three patients on the ward now and we are training our staff using butaperazine (which is apparently quite successful). I anticipate no further difficulty in obtaining approval and believe it should be forthcoming shortly.

(4) Fenfluramine Exhibit for APA: I regret to tell you that when I called the exhibition manager of the APA he indicated that we were much too late to apply for space, the deadline having been January 1. I am disappointed and accept the responsibility for not anticipating this deadline. As I thought about the kind of exhibit I wish to make, it occurred to me that we might try such a display at the forthcoming International EEG meetings in San Diego (September 14-20, 1969). If it is successful there, perhaps we would like to use that material for the APA in 1970.

We missed our luncheon appointment early in February. What are the chances of getting together during the next month?

Sincerely yours,

March 13, 1969

Dr. William R. Tabor
Director, Medical Research
A. H. Robbins Company
Professor of Psychiatry
1407 Cummings Drive
Richmond, Virginia 23220

MF:kp

Dear Bill,
P.S. Approval for the AHR-1900 study has just been received. The forms that you suggested should be sent as soon as practicable. (1) Tysmate paper on Drug Dependence: We have the galley proof on the Tysmate report from the Journal of Clinical Pharmacology and have ordered 300 reprints for our use. If Mrs. Carnes would like to order an additional supply, please have her call my secretary.

(2) Butaperazine Syrum Study: This study has appeared in Current Therapeutic Research; however, we have not yet received reprints.

(3) AHR-1900: With regard to Mr. Banner and the City of New York with regard to AHR-1900, I called him and he was principally interested in a general statement about AHR-1900. After our discussion he indicated that he would approve this study. He was surprised by the request from the Commissioner of Hospitals, indicating that this was the first such request that he had received in twenty years. We have three patients on the ward now and we are training our staff using butaperazine (which is apparently quite successful). I anticipate no further difficulty in obtaining approval and believe it should be forthcoming shortly.

(4) Fenfluramine Exhibit for APA: I regret to tell you that when I called the exhibition manager of the APA he indicated that we were much too late to apply for space, the deadline having been January 1. I am disappointed and accept the responsibility for not anticipating this deadline. As I thought about the kind of exhibit I wish to make, it occurred to me that we might try such a display at the forthcoming International EEG meetings in San Diego (September 14-20, 1969). If it is successful there, perhaps we would like to use that material for the APA in 1970.

March 12, 1969

Dr. Oldrich Vinar
The George Washington University
Biometric Laboratory
1145 Nineteenth Street, N.W., Room 618
Washington, D.C. 20036

Dear Dr. Vinar:

After I spoke to you yesterday my secretary reminded me that May 6 and 7 are within the dates of the American Psychiatric Association meetings (May 5-9, Miami Beach). These are among the most useful meetings of our colleagues. I think you would enjoy attending the meetings and I am sure that Dr. Lehmann and other American members of the CINP will probably prefer to attend.

Is there still time to arrange the meeting of the Program Committee to follow the conference on neuroleptics in Liege?

If necessary, we can forego the APA meetings, but I am sure you will agree that attendance at both may be more profitable.

If it is possible for you to visit us, I am sure Professor Roubicek and Dr. Volavka will join me in making your visit interesting.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp